Article
Oncology
Karin Bauer, Sigrid Machherndl-Spandl, Lukas Kazianka, Irina Sadovnik, Sinan Gueltekin, Susanne Suessner, Johannes Proell, Jeroen Lauf, Gregor Hoermann, Gregor Eisenwort, Norman Haefner, Mathilde Foedermayr-Mayrleitner, Ann-Sofie Schmolke, Emiel van der Kouwe, Uwe Platzbecker, Thomas Lion, Ansgar Weltermann, Otto Zach, Gerald Webersinke, Ulrich Germing, Christian Gabriel, Wolfgang R. Sperr, Marie C. Bene, Philipp B. Staber, Peter Bettelheim, Peter Valent
Summary: We have identified the Coxsackie-Adenovirus receptor (CAR) as a relevant marker that is downregulated in erythroid progenitor cells (EP) in myelodysplastic syndromes (MDS). Lentiviral transduction of the full-length CXADR gene increased the expression of early erythroid antigens and cell migration. Conditional knock-out of Cxadr in mice resulted in anemia and erythroid dysplasia. Decreased CAR expression on EP correlated with high-risk MDS and decreased survival, indicating its prognostic significance.
Review
Pharmacology & Pharmacy
Tomasz M. Grzywa, Dominika Nowis, Jakub Golab
Summary: CECs play diverse roles in immune response, from affecting vulnerability to infectious diseases in neonates, regulating feto-matemal tolerance in pregnant women, to influencing immune response in patients with cancer. Their mechanisms include suppressing proinflammatory responses, decreasing T-cell proliferation and promoting T-cell differentiation into regulatory T-cells.
PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Chemistry, Medicinal
Hana Votavova, Zuzana Urbanova, David Kundrat, Michaela Dostalova Merkerova, Martin Vostry, Monika Hruba, Jaroslav Cermak, Monika Belickova
Summary: DFX improves hematopoiesis in anemic myelodysplastic syndrome patients by modulating immune response, suppressing negative regulators of blood cell differentiation, and upregulating heme metabolism.
Article
Hematology
Antonio Piga, Filomena Longo, Maria Rita Gamberini, Ersi Voskaridou, Paolo Ricchi, Vincenzo Caruso, Antonello Pietrangelo, Xiaosha Zhang, Jeevan K. Shetty, Kenneth M. Attie, Immacolata Tartaglione
Summary: This study reported the long-term safety and efficacy of luspatercept in beta-thalassemia patients, showing sustained increases in hemoglobin levels in NTD patients and sustained reductions in transfusion burden in TD patients.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2022)
Article
Medicine, Research & Experimental
Abbas Rahdar, Mohammad Reza Hajinezhad, Saman Sargazi, Muhammad Bilal, Mahmood Barani, Pouya Karimi, George Z. Kyzas
Summary: Deferasirox formulated in microemulsions shows improved bioavailability and anti-lipid peroxidation effects, with lower toxicity in treating iron-intoxicated rats. DFX-loaded microemulsions have the potential to reduce serum biochemical parameters and oxidative stress.
Review
Biochemistry & Molecular Biology
Marta Araujo-Castro, Eider Pascual-Corrales, Javier Molina-Cerrillo, Teresa Alonso-Gordoa
Summary: Research on immunotherapy for adrenocortical carcinoma indicates limited efficacy, lack of reliable predictors of response, and potential resistance mechanisms.
Article
Oncology
Uwe Platzbecker, Katharina S. Goetze, Philipp Kiewe, Ulrich Germing, Karin Mayer, Markus Radsak, Thomas Wolff, Joerg Chromik, Katja Sockel, Uta Oelschlaegel, Detlef Haase, Thomas Illmer, Haifa Kathrin Al-Ali, Gerda Silling, Joseph G. Reynolds, Xiaosha Zhang, Kenneth M. Attie, Jeevan K. Shetty, Aristoteles Giagounidis
Summary: This study reports the long-term safety and efficacy of luspatercept in patients with transfusion-dependent lower-risk myelodysplastic syndromes. The study highlights the high rates of hematologic improvement observed, particularly in non-RS and non-transfusion-dependent patients. These findings provide a platform for future trials and expand our understanding of luspatercept's effects in different subtypes of MDS.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Letter
Medicine, General & Internal
Eleftherios Mylonakis, Christina Barkauskas, Garyfallia Poulakou, Barnaby E. Young
Summary: This is a multinational clinical trial that compared ensovibep, a designed ankyrin repeat protein, with standard of care to evaluate its effectiveness in improving outcomes of hospitalized COVID-19 patients.
ANNALS OF INTERNAL MEDICINE
(2023)
Article
Pediatrics
Rajeswari Rethinaswamy DivakarJose, C. G. Delhikumar, G. Ram Kumar
Summary: The study aimed to evaluate the efficacy and safety of dual oral iron chelation therapy in reducing iron overload in transfusion-dependent thalassemic children. The results showed a significant decrease in serum ferritin levels with the combination therapy, while liver and myocardial iron concentrations did not change significantly. Adverse effects such as red color urine and transient elevation in creatinine and liver enzymes were observed during the study period.
INDIAN JOURNAL OF PEDIATRICS
(2021)
Article
Biochemistry & Molecular Biology
Yi Feng, Shaon Borosha, Anamika Ratri, Eun Bee Lee, Huizhen Wang, Timothy A. Fields, William H. Kinsey, Jay L. Vivian, M. A. Karim Rumi, Patrick E. Fields
Summary: Erythropoietin (EPO) signaling regulates calcium influx through TRPC2 and TRPC6 proteins in erythropoiesis. This study reveals that DOT1L regulates TRPC6 gene expression in erythroid progenitor cells, and loss of DOT1L leads to accelerated calcium influx through TRPC2 and detrimental effects on HPCs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Daniel N. Mangel, Gabriel J. Juarez, Stephanie H. Carpenter, Axel Steinbrueck, Vincent M. Lynch, Jian Yang, Adam C. Sedgwick, Aaron Tondreau, Jonathan L. Sessler
Summary: In this study, the use of deferasirox derivatives as lanthanide chelators was reported, and the complexation behavior of these derivatives in solid state and solution was investigated. High selectivity for Lu(III) was observed in competitive precipitation.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2023)
Review
Biochemistry & Molecular Biology
Sarunya Kitdumrongthum, Dunyaporn Trachootham
Summary: Since legalization, cannabis/marijuana has become a functional ingredient in food and has gained attention. Key compounds like THC, CBD, and other cannabinoids have various health benefits, but the response to cannabis varies among individuals. Factors like delivery route, duration, frequency, age, sex, and genetics can affect the response to cannabis products. To ensure safety, starting with a low dose and gradually increasing is recommended.
Editorial Material
Hematology
Carsten Utoft Niemann
Summary: This study compares the adverse event burden of continuous acalabrutinib versus ibrutinib treatment in CLL. The improved treatment options for CLL in recent years have raised important questions about risk-benefit differences between different treatment options and patient subgroups.
Article
Rheumatology
Jack Arnold, Shouvik Dass, Sarah Twigg, Colin H. Jones, Ben Rhodes, Peter Hewins, Mithun Chakravorty, Phil Courtney, Michael Ehrenstein, Md Yuzaiful Md Yusof, Edward M. Vital
Summary: Obinutuzumab appears to be effective and steroid-sparing in SLE patients with secondary non-response to rituximab.
Review
Immunology
Mengfei Cheng, Shuo Zhang, Jiahui Liu, Shuai Jiang, Mei Dong
Summary: This review examines the pharmacokinetics and pharmacodynamics of ICIs, factors influencing their safety and efficacy, exposure-response relationships, as well as concentration and time-dependent changes. Various covariates affecting exposure such as PK and PD characteristics, E-R relationships, and changes in drug concentration over time were explored to assess the efficacy and safety of ICIs.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Letter
Oncology
Sabrina Mariani, Silvia Maria Trisolini, Clara Minotti, Massimo Breccia, Claudio Cartoni, Maria Stefania De Propris, Giovanna Loglisci, Roberto Latagliata, Maria Zaira Limongi, Anna Maria Testi, Robin Foa, Saveria Capria
LEUKEMIA & LYMPHOMA
(2021)
Review
Hematology
Emilia Scalzulli, Sara Pepe, Gioia Colafigli, Massimo Breccia
Summary: Myelodysplastic syndromes (MDS) are a group of myeloid disorders with increased risk of acute leukemia transformation. Treatment of MDS is based on risk stratification, aiming to improve patients' quality of life and survival. New drugs are being developed based on molecular and immunological pathways for personalized therapy in the future.
Article
Health Care Sciences & Services
Claudio Cartoni, Massimo Breccia, Johannes Maria Giesinger, Erminia Baldacci, Ida Carmosino, Giorgia Annechini, Giovanna Palumbo, Daniele Armiento, Pasquale Niscola, Andrea Tendas, Gregorio Antonio Brunetti, Clara Minotti, Maria Giulia Marini, Luigi Reale, Nicoletta Martone, Maurizio Martelli, Fabio Efficace
Summary: This study compared early palliative home care with standard hospital care for patients with hematologic malignancies, finding that home care patients had fewer blood transfusions and lower infection rates, leading to cost savings for the health provider. The results suggest that early palliative home care may be a cost-effective option for these patients.
JOURNAL OF PALLIATIVE MEDICINE
(2021)
Letter
Oncology
Francesca Palandri, Giuseppe Alberto Palumbo, Elena Maria Elli, Nicola Polverelli, Giulia Benevolo, Bruno Martino, Elisabetta Abruzzese, Mario Tiribelli, Alessia Tieghi, Roberto Latagliata, Francesco Cavazzini, Micaela Bergamaschi, Gianni Binotto, Monica Crugnola, Alessandro Isidori, Giovanni Caocci, Florian Heidel, Novella Pugliese, Costanza Bosi, Daniela Bartoletti, Giuseppe Auteri, Daniele Cattaneo, Luigi Scaffidi, Malgorzata Monica Trawinska, Rossella Stella, Fiorella Ciantia, Fabrizio Pane, Antonio Cuneo, Mauro Krampera, Gianpietro Semenzato, Roberto Massimo Lemoli, Alessandra Iurlo, Nicola Vianelli, Michele Cavo, Massimo Breccia, Massimiliano Bonifacio
BLOOD CANCER JOURNAL
(2021)
Editorial Material
Medicine, Research & Experimental
Massimo Breccia
ADVANCES IN THERAPY
(2021)
Article
Hematology
Emilia Scalzulli, Giovanni Caocci, Fabio Efficace, Lorenzo Rizzo, Gioia Colafigli, Alessio Di Prima, Sara Pepe, Danilo Alunni Fegatelli, Ida Carmosino, Daniela Diverio, Roberto Latagliata, Giorgio La Nasa, Maurizio Martelli, Robin Foa, Massimo Breccia
Summary: This study suggests that dasatinib and nilotinib used as second-line treatment in CP-CML are equally effective in a real-life setting, with high molecular response rates and acceptable tolerability.
ANNALS OF HEMATOLOGY
(2021)
Article
Oncology
Giulia Benevolo, Elena M. Elli, Daniela Bartoletti, Roberto Latagliata, Mario Tiribelli, Florian H. Heidel, Francesco Cavazzini, Massimiliano Bonifacio, Monica Crugnola, Gianni Binotto, Alessandra D'Addio, Alessia Tieghi, Micaela Bergamaschi, Giovanni Caocci, Nicola Polverelli, Elisa Bossi, Giuseppe Auteri, Ida Carmosino, Lucia Catani, Antonio Cuneo, Mauro Krampera, Francesco Lanza, Roberto M. Lemoli, Nicola Vianelli, Massimo Breccia, Giuseppe A. Palumbo, Michele Cavo, Francesca Palandri
Summary: The study found that in patients with PV, a BMI >= 25 was associated with a lower probability of progression to PPV-MF and better survival. On the other hand, CCI >= 1 did not affect progression to PPV-MF or survival.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Oncology
Roberto Latagliata, Immacolata Attolico, Malgorzata Monika Trawinska, Isabella Capodanno, Mario Annunziata, Chiara Elena, Luigiana Luciano, Monica Crugnola, Micaela Bergamaschi, Massimiliano Bonifacio, Claudia Barate, Endri Mauro, Gianni Binotto, Nicola Sgherza, Chiara Aguzzi, Barbara Monteleone, Federica Sora, Giovanni Caocci, Debora Luzi, Elena Mariggio, Luigi Scaffidi, Daniele Cattaneo, Antonella Gozzini, Ambra Di Veroli, Elisabetta Abruzzese, Sara Galimberti, Alessandra Iurlo, Giorgina Specchia, Massimo Breccia
Summary: The study evaluated the effectiveness and safety profile of bosutinib in elderly patients aged over 65 years with chronic myeloid leukemia. Results showed that bosutinib had a favorable efficacy and safety profile, being effective even in patients with comorbidities, resistance, and intolerance to previous treatments. This suggests that bosutinib could play a significant role in current clinical practice, particularly for frail patients.
HEMATOLOGICAL ONCOLOGY
(2021)
Review
Hematology
Fabio Efficace, Marco Vignetti, Francesco Sparano, Emilia Scalzulli, Massimo Breccia
Summary: The treatment landscape of CML is challenging and HRQOL data is crucial; recent studies show TKIs impact patients' HRQOL, but further research is needed.
EXPERT REVIEW OF HEMATOLOGY
(2021)
Article
Pharmacology & Pharmacy
Massimo Breccia, Gioia Colafigli, Emilia Scalzulli, Maurizio Martelli
Summary: Tyrosine kinase inhibitors (TKIs) have significantly improved outcomes for CML patients, but resistance and intolerance can still be issues. Asciminib, an allosteric inhibitor, shows promise as a third-line treatment option, particularly for patients with the T315I mutation.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2021)
Review
Hematology
Massimo Breccia, Fabio Efficace, Emilia Scalzulli, Giulia Ciotti, Giacomo Maestrini, Gioia Colafigli, Maurizio Martelli
Summary: Prognostic factors examined at baseline are crucial for evaluating long-term disease-related death probability, potential toxicities, and projected overall survival. Genomic assessment offers a genomic-based risk stratification and aids in decision-making process based on patient's specific conditions.
EXPERT REVIEW OF HEMATOLOGY
(2021)
Article
Oncology
Lidia Borghi, Gianantonio Rosti, Alessandro Maggi, Massimo Breccia, Eros Di Bona, Alessandra Iurlo, Gaetano La Barba, Paolo Sportoletti, Francesco Albano, Sara Galimberti, Flavia Rivellini, Giovanna Rege Cambrin, Isabella Capodanno, Antonio Cuneo, Massimiliano Bonifacio, Simona Sica, Luca Arcaini, Enrico Capochiani, Claudia Minotto, Fabio Ciceri, Monica Crugnola, Luigi Di Caprio, Sharon Supekar, Chiara Elena, Michele Baccarani, Elena Vegni
Summary: The study aims to evaluate patients' psycho-emotional characteristics and quality of life after stopping nilotinib treatment and entering TFR. It will assess psychological variables in-depth to determine the need for personalized patient care and counseling, and guide clinicians in considering the psychological well-being of patients considering treatment termination.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Fabio Andreozzi, Fulvio Massaro, Sebastian Wittnebel, Chloe Spilleboudt, Philippe Lewalle, Adriano Salaroli
Summary: For decades, intensive chemotherapy (IC) has been considered the best therapeutic option for treating acute myeloid leukemia (AML). Recently, several new drugs have emerged, providing new opportunities and challenges for the treatment of both fit and unfit AML patients. Access to and inclusion in clinical trials of these new drugs should be encouraged to define the future standard of treatment for AML.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Letter
Oncology
Oliver G. Ottmann, Frank Stegelmann, Massimo Breccia, Juan Luis Steegmann, Eduardo Olavarria, Paola Aimone, Jeffrey H. Lipton
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
Fabio Efficace, Alessandra Iurlo, Andrea Patriarca, Fabio Stagno, Ping-Chong Bee, Genevieve Ector, Isabella Capodanno, Chiara Elena, Massimiliano Bonifacio, Nicole M. A. Blijlevens, Giovanni Caocci, Chonghua Wan, Elisabetta Abruzzese, Massimo Breccia, Francesco Cottone, Iris Okumura, Simone Oerlemans, Nicola Cascavilla, Francesco Albano, Vamsi Kota, Monika Sztankay, Maria Cristina Miggiano, Susanne Saussele, Nicola Di Renzo, Federica Sora, Fausto Castagnetti, Michele Baccarani, Marco Vignetti, Gianantonio Rosti
Summary: The study validated the EORTC QLQ-CML 24 questionnaire with 782 CML patients internationally, indicating its value in assessing HRQOL in CML patients. Internal consistency, assessed with Cronbach's alpha coefficients, ranged from 0.66 to 0.83, and reference values stratified by age and sex were generated for future studies.
LEUKEMIA & LYMPHOMA
(2021)